---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-001470"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T11:54:43.361970+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Charles River Q3 revenue $989.2M (+10.4% YoY); raises guidance, plans Avian Vaccine sale for ~$170M

## Summary
- Q3 revenue $989.2M (+10.4% YoY, organic +15.3%); GAAP EPS $1.88 (-6.5%), non-GAAP EPS $2.63 (-2.6%).
- DSA segment revenue $619.5M (+16.5%) drove results; Manufacturing declined -1.7% to $189.6M.
- Narrows 2022 guidance: reported revenue growth 10-11%, non-GAAP EPS $10.80-10.95 (prior $10.70-10.95).
- Announced divestiture of Avian Vaccine business for ~$170M cash plus up to $30M contingent; close expected by year-end.
- Divestiture to reduce 2023 revenue by ~$80M and non-GAAP EPS by ~$0.35 before redeployment of proceeds.

## SEC filing metadata
- accession: 0001157523-22-001470
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000115752322001470/0001157523-22-001470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000115752322001470/a52958171.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-001470
- JSON: https://secwatch.observer/filing/0001157523-22-001470.json
- Plain text: https://secwatch.observer/filing/0001157523-22-001470.txt

## Key facts
- Earnings Releases
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported third quarter ended September 24, 2022 results: revenue $989.2 million, net income $96.5 million, EPS $1.88. Guidance reaffirmed.
  - Period: third quarter ended September 24, 2022
  - Revenue: $989.2 million
  - Net income: $96.5 million
  - EPS: $1.88
  - Guidance: reaffirmed
  - Result: reported results
  source text: EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a52958171ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2022 Results – Third-Quarter Revenue of $989.2 Million – – Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 – – Narrows 2022 Revenue Growth and Earnings Per Share Guidance – – Announces Planned
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000115752322001470/0001157523-22-001470-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.